Results 111 to 120 of about 26,895 (263)

SGLT2 Inhibitors in Liver Patients [PDF]

Clinical Gastroenterology and Hepatology, 2020
John Chen Hsiang, Vincent Wai-Sun Wong
openaire   +2 more sources

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome
Background Cancer patients with diabetes are at increased risk for cardiovascular diseases due to common risk factors and well-documented drug-associated cardiotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown cardiovascular benefits
Hsiao-Huai Kuo, Kuang-Te Wang, Hsin-Hao Chen, Zih-Yin Lai, Po-Lin Lin, Yung-Jen Chuang, Lawrence Yu-Min Liu   +6 more
doaj   +1 more source

Association Between SGLT2 Inhibitor Therapy and the Incidence of Tinnitus in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Audiology Research
Background: Numerous studies have demonstrated the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiovascular and renal outcomes in patients with heart failure and chronic kidney disease.
David Ulrich Seidel, Simon Bode, Karel Kostev   +2 more
doaj   +1 more source

Ketoacidosis and SGLT2 Inhibitors: A Narrative Review

Metabolites
An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with the occurrence of a particular type of DKA defined as euglycemic (euDKA), characterized by glycemic ...
Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina T. Russo, Herbert Ryan Marini   +10 more
openaire   +4 more sources

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study

Archives of Medical Science
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects.
Ke-Hsin Ting, Jing-Yang Huang, Pei-Lun Liao, Chia-Yi Lee, Shun-Fa Yang   +4 more
doaj   +1 more source

Risk of perioperative discontinuation of SGLT2 inhibitors

British Journal of Anaesthesia
When sodium-glucose cotransporter-2 (SGLT2) inhibitors were primarily prescribed for treatment of diabetes mellitus, guidelines recommended withholding SGLT2 inhibitors before surgery to mitigate the associated risk of ketoacidosis. However, currently, SGLT2 inhibitors are an established therapy for patients with heart failure, and there is evidence ...
Maartina J.P. Oosterom-Eijmael, Jeroen Hermanides, Daniel H. van Raalte, Abraham H. Hulst   +3 more
openaire   +3 more sources

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction

ESC Heart Failure
Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Standard Care in ...
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford   +7 more
doaj   +1 more source